Cancer therapy has always been a challenging field, with the need to balance efficacy and minimize side effects. Traditional treatments often lack precision, leading to systemic toxicity and reduced patient quality of life. In recent years, the development of drug-based nanostructures has emerged
In recent developments, a collaborative research team led by the University of Arizona College of Medicine – Tucson has discovered groundbreaking potential for an FDA-approved osteoporosis drug in the treatment of a rare genetic heart disease. The heart condition in question is dilated c
Chordoma, a rare bone cancer affecting about one in a million people, has long been a medical enigma. Historically, the lack of understanding and effective treatments has rendered it untreatable. However, recent breakthroughs by Professor Paul Workman and his team offer new hope. This article
AI is revolutionizing precision and personalized oncology care by enabling more accurate diagnoses, predicting patient outcomes, and tailoring treatments to individual needs. Through advanced algorithms and machine learning, AI can analyze vast amounts of data, including medical records, genetic
Huntington’s disease (HD), a devastating inherited neurodegenerative disorder, typically manifests in adulthood, progressively impairing motor functions, cognitive capabilities, and overall brain function over approximately 15 to 20 years post-diagnosis. Despite the discovery over three decades ago
In an unexpected turn of events that sent ripples through the biotechnology sector, Pliant Therapeutics' shares experienced a dramatic plunge after the company voluntarily halted the Phase 2b/3 trial of its experimental fibrosis drug, bexotegrast. The decision, advised by a clinical trial
